(R)-N-(tert-butyloxycarbonyl)-α-ethylbenzylamine | 1006877-01-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-N-(tert-butyloxycarbonyl)-α-ethylbenzylamine
• 英文别名: (1-phenyl-propyl)-carbamic acid tert-butyl ester；(R)-tert-butyl 1-phenylpropylcarbamate；tert-butyl (R)-1-phenylpropylcarbamate；1,1-Dimethylethyl N-[(1R)-1-phenylpropyl]carbamate；tert-butyl N-[(1R)-1-phenylpropyl]carbamate
• CAS: 1006877-01-5
• 化学式: C₁₄H₂₁NO₂
• 分子量: 235.326
• InChiKey: ZOMRHAXWDHLHLB-GFCCVEGCSA-N

物化性质

• 熔点：
  68 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  340.4±21.0 °C(Predicted)
• 密度：
  1.003±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  硼酸三甲酯 、 (R)-N-(tert-butyloxycarbonyl)-α-ethylbenzylamine 在 叔丁基锂 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 4.5h， 生成
  参考文献：
  名称：

  New C5-Alkylated Indolobenzazepinones Acting as Inhibitors of Tubulin Polymerization: Cytotoxic and Antitumor Activities

  摘要：

  A series of 5-alkylindolobenzazepin-7-ones was synthesized by Suzuki coupling between 3-iodoindole-2-carboxylates and the appropriate alpha-alkylbenzylamino o-boronic acids followed by cyclization to the lactam. Derivatives having a linear alkyl chain at C5 were found to be highly cytotoxic to KB cells with IC50 values in the 30-80 nM range. These compounds also inhibited the polymerization of tubulin with IC50's of 1-2 mu M. Compound 4f ((S)-5-ethyl) showed comparable antiproliferative activities (IC50's of 30-70 nM) in a variety of cancer cell lines, cell growth being arrested at the G2/M phase. Compound 4f induced apoptosis in a dose-dependent manner in three different cancer cell lines and was shown to affect cell morphology in a manner consistent with its inhibitory action on tubulin polymerization. Using the experimental model of glioma grafted on the chick chorio-allantoic membrane, local treatment with compound 4f markedly reduced tumor progression.

  DOI：

  10.1021/jm701466p
• 作为产物：
  描述：

  N-Boc-(p-methoxyphenyl)benzylamine 在 正丁基锂 、 ammonium cerium(IV) nitrate 、 鹰爪豆碱 作用下， 反应 10.0h， 生成 (R)-N-(tert-butyloxycarbonyl)-α-ethylbenzylamine
  参考文献：
  名称：

  (−)-Sparteine-Mediated α-Lithiation of N-Boc-N-(p-methoxyphenyl)benzylamine:  Enantioselective Syntheses of (S) and (R) Mono- and Disubstituted N-Boc-benzylamines

  摘要：

  DOI：

  10.1021/ja9538804

文献信息

• [EN] NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES<br/>[FR] AGONISTES DU RÉCEPTEUR A DU PEPTIDE NATRIURÉTIQUE UTILES POUR LE TRAITEMENT DE MALADIES CARDIOMÉTABOLIQUES, D'UNE MALADIE RÉNALE ET DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2020236688A1

  公开（公告）日：2020-11-26

  The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.

  本发明涉及公式I的化合物：I及其药用可接受的盐或前药。本发明还涉及包含至少一种公式I化合物的组合物，以及使用公式I化合物治疗心脏代谢疾病，包括高血压、心力衰竭、肾脏疾病和糖尿病的方法。
• Novel bifunctional thiourea–ammonium salt catalysts derived from amino acids: application to highly enantio- and diastereoselective aza-Henry reaction
  作者：Hong-Yu Wang、Zhuo Chai、Gang Zhao

  DOI：10.1016/j.tet.2013.04.079

  日期：2013.6

  development of new efficient and easily accessible catalysts has been one of the focuses in asymmetric phase-transfer catalysis. In this paper, a novel class of chiral bifunctional thiourea–ammonium phase-transfer catalysts were synthesized from commercially available α-amino acids. The structural modularity of these catalysts permits facile tunings to achieve optimum results, which was demonstrated

  新型高效且易于获得的催化剂的开发一直是不对称相转移催化的重点之一。在本文中，从市场上可买到的α-氨基酸合成了一类新型的手性双官能硫脲-铵相转移催化剂。这些催化剂的结构模块性使其易于调节以获得最佳结果，这在催化氮杂-亨利反应中表现出优异的对映选择性（高达99.5％ee）和非对映选择性（高达> 25：1 dr）得到了证明。
• Catalytic Enantioselective Addition of Organometallic Reagents to <i>N</i>-Formylimines Using Monodentate Phosphoramidite Ligands
  作者：Maria Gabriella Pizzuti、Adriaan J. Minnaard、Ben L. Feringa

  DOI：10.1021/jo702140f

  日期：2008.2.1

  The asymmetric synthesis of protected amines via the copper/phosphoramidite-catalyzed addition of organozinc and organoaluminum reagents to N-acylimines, generated in situ from aromatic and aliphatic α-amidosulfones, is reported. High yields of optically active N-formyl-protected amines and enantioselectivities up to 99% were obtained. Under the reaction conditions, partial oxidation of the phosphoramidite

  据报道，通过芳族和脂肪族α-酰胺基砜原位生成的铜/次膦酸酯催化的有机锌和有机铝试剂向N-酰基嘧啶的加成反应，不对称合成了受保护的胺。获得了高产率的旋光性N-甲酰基保护的胺，对映选择性高达99％。在反应条件下，检测到亚磷酰胺配体被部分氧化为相应的磷酸酰胺。初步研究了其起源及其对催化加成反应的影响。
• Novel pyrrolidine compound and a process for preparing the same
  申请人：Moritani Yasunori

  公开号：US20070167440A1

  公开（公告）日：2007-07-19

  The present invention relates to a novel pyrrolidine compound, which has a potent antagonistic activity against central cannabinoid (CB1) receptor, having the formula [I]: wherein each of R 1 and R 2 is (A) optionally substituted aryl (or heteroaryl) group, or (B) both of the groups combine to form a group of the formula: one of R 3 and R 4 is hydrogen and another is hydrogen, hydroxyl, hydroxyalkyl, etc., or both of R 3 and R 4 combine to form oxo group, R 5 is hydrogen or alkyl, Y is single bond, oxygen atom or a group of the formula: —N(R 7 )—, R 6 is optionally substituted hydrocarbon group or optionally substituted cyclic group, R 7 is alkyl or alkyloxycarbonylalkyl, provided that R 6 is not 4-amino-5-chloro-2-methoxyphenyl group when Y is single bond and one of the R 3 and R 4 is hydrogen and another is hydroxymethyl, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种新型吡咯烷化合物，其具有对中枢大麻素（CB1）受体的强烈拮抗活性，其化学式为[I]：其中，R1和R2中的每一个是（A）可选取的取代芳基（或杂环芳基）基团，或者（B）两个基团结合形成式的基团：R3和R4中的一个是氢，另一个是氢、羟基、羟基烷基等，或者R3和R4结合形成氧代基团，R5是氢或烷基，Y是单键、氧原子或式的基团：—N(R7)—，R6是可选取的取代的碳氢基团或可选取的取代的环状基团，R7是烷基或烷氧羰基烷基，但当Y为单键且R3和R4中的一个为氢，另一个为羟甲基时，R6不是4-氨基-5-氯-2-甲氧基苯基团，或其药学上可接受的盐。
• BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS
  申请人：Harris Joel M.

  公开号：US20110065671A1

  公开（公告）日：2011-03-17

  The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bi-cyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.

  本发明涉及式(I)的二环杂环衍生物，包括一种二环杂环衍生物的组合物，并且还涉及使用这些二环杂环衍生物来治疗或预防患者的肥胖症、糖尿病、代谢障碍、心血管疾病或与GPR1 19活性相关的疾病的方法。